H. Jeffery Wilkins M.D.
Net Worth

Last updated: 10 Dec 2021

What is H. Jeffery Wilkins M.D. net worth?

The estimated net worth of Dr. H. Jeffery Wilkins M.D. is at least $4,755,496 as of 10 Dec 2021. He owns shares worth $376,136 as insider and has received compensation worth at least $4,379,360 in Avalo Therapeutics, Inc. and Cerecor Inc..

What is the salary of H. Jeffery Wilkins M.D.?

Dr. H. Jeffery Wilkins M.D. salary is $547,420 per year as Chief Medical Officer in Avalo Therapeutics, Inc.. He also receives $547,420 as Chief Medical Officer in Cerecor Inc..

How old is H. Jeffery Wilkins M.D.?

Dr. H. Jeffery Wilkins M.D. is 63 years old, born in 1962.

What stocks does H. Jeffery Wilkins M.D. currently own?

As insider, Dr. H. Jeffery Wilkins M.D. owns shares in 2 companies:

Company	Title	Shares	Price per share	Total value
Avalo Therapeutics, Inc. (AVTX)	Chief Medical Officer	33,373	$8.9	$297,020
Cerecor Inc. (CERC)	Chief Medical Officer	27,002	$2.93	$79,116

What does Avalo Therapeutics, Inc. do?

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

AVTX

Avalo Therapeutics, Inc.

$8.9

What does Cerecor Inc. do?

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.